|
Jeff Himawan, PhD, has over 20 years of experience as a scientist, entrepreneur and venture capitalist. He began his industrial career in 1987 as a bench scientist at Genzyme Corporation. In 1996, Dr. Himawan co-founded Seed-One Ventures, a venture capital firm that specializes in the initial formation, financing, and early operational development of technology-based companies. As a Managing Director at Seed-One Ventures, he led the formation and management of Elusys Therapeutics, a Fund IV company. Dr. Himawan joined Essex Woodlands in 2001. He serves on the Board of Directors of Iomai, Receptor BioLogix, MediciNova, Light Sciences Oncology and Symphogen. Dr. Himawan holds a Bachelor of Science degree from the Massachusetts Institute of Technology and a PhD degree from Harvard University. He has written several patents in the fields of wireless communications, biotechnology, and protein chemistry. | 